Zoetis

Zoetis Foundation Announces $2.6 Million in Grants to Advance Opportunities for Veterinarians and Livestock Farmers

Retrieved on: 
Thursday, September 7, 2023

Today, the Zoetis Foundation announced that it will distribute $2.6 million during its second round of 2023 grants, supporting six initiatives to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals.

Key Points: 
  • Today, the Zoetis Foundation announced that it will distribute $2.6 million during its second round of 2023 grants, supporting six initiatives to help enable thriving professions and livelihoods for livestock farmers and veterinary professionals.
  • This year, the Foundation is proud to expand its support of veterinary mental health and wellness to Australia and the United Kingdom.
  • The CRG Philanthropy Grants Program invites Zoetis’ CRGs to propose grantee suggestions to the Zoetis Foundation for possible funding.
  • The Zoetis Foundation is a private charitable organization and is solely funded by Zoetis Inc. , with distinct legal requirements and restrictions.

Zoetis to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

Retrieved on: 
Wednesday, September 6, 2023

Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, Sept. 12, 2023.
  • Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts.
  • Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations .
  • A replay of the presentation will also be available on the Zoetis website at the conclusion of the event.

Global Veterinary Biomarkers Market Size/Share Envisaged to Reach USD 2,554.79 Million By 2032, at CAGR 12.3%: Polaris Market Research

Retrieved on: 
Thursday, August 31, 2023

Explore customized purchase options

Key Points: 
  • Explore customized purchase options
    R&D by companies: Rising emphasis on increasing research and development activities by leading companies to improve biomarker portfolios is fueling the veterinary biomarkers market growth.
  • Also, the rising trend of adopting pets from shelters and rescue organizations is boosting the veterinary biomarkers market growth.
  • Cases of cancer and cardiovascular diseases: Veterinary biomarkers are used in veterinary applications to detect and diagnose diseases in the initial stages.
  • Polaris Market Research has segmented the veterinary biomarkers market report based on animal type, product type, application, disease type, and region:

Dexcom Appoints Rimma Driscoll to Board of Directors

Retrieved on: 
Monday, August 28, 2023

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023.

Key Points: 
  • DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Rimma Driscoll to its Board of Directors, effective August 24, 2023.
  • Ms. Driscoll is an accomplished leader with significant experience developing, guiding and executing organic and inorganic growth strategies for global organizations.
  • In this role, Ms. Driscoll oversees the company’s global business strategy, the execution of commercial launch plans, external business development and integration efforts, and has oversight for Zoetis’ Global BioDevices business.
  • “We are very excited to welcome Rimma to the Dexcom Board,” said Kevin Sayer, chairman, president and CEO at Dexcom.

Zoetis Welcomes Officials to Celebrate New R&D Building in Durham, N.C.

Retrieved on: 
Thursday, August 24, 2023

The expanded site serves as the hub for Zoetis’ engineering and diagnostics work including device reliability testing.

Key Points: 
  • The expanded site serves as the hub for Zoetis’ engineering and diagnostics work including device reliability testing.
  • Zoetis has added 54 jobs to its diagnostics and biodevices research and development team in Durham in the last three years.
  • Zoetis’ site in Durham, N.C., is a crucial part of the company’s global research and development locations around the world.
  • “We are thrilled to celebrate our new building in Durham, where our research and development team dedicated to diagnostics and engineering is based.

Zoetis Welcomes Officials to Open New State-of-the-Art Facility in Lincoln

Retrieved on: 
Wednesday, August 9, 2023

Source: Zoetis

Key Points: 
  • Source: Zoetis
    Today, Zoetis, the world leader in Animal Health, marked the official opening of its new monoclonal antibodies (mAbs) expansion with a ribbon cutting ceremony at its site in Lincoln, Neb.
  • Senator Pete Ricketts, Lincoln Mayor Gaylor Baird and key company leaders including Zoetis CEO Kristin Peck, and President of Global Manufacturing and Supply, Nick Ashton.
  • Located on 145 acres in the west side of Lincoln, Neb., the campus spans 1.4 million square feet, housing manufacturing, testing, and facility support buildings.
  • More recent incarnations of these animal health companies, including Zoetis, have continued to play an important economic role in the Lincoln community.

Zoetis Announces Second Quarter 2023 Results

Retrieved on: 
Tuesday, August 8, 2023

(NYSE:ZTS) today reported its financial results for the second quarter of 2023 and updated its guidance for full year 2023.

Key Points: 
  • (NYSE:ZTS) today reported its financial results for the second quarter of 2023 and updated its guidance for full year 2023.
  • The company reported revenue of $2.2 billion for the second quarter of 2023, an increase of 6% compared with the second quarter of 2022.
  • On an operational1 basis, revenue for the second quarter of 2023 increased 9% compared with the second quarter of 2022, excluding the impact of foreign currency.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review second quarter 2023 results, discuss financial guidance and respond to questions from financial analysts.

Zoetis Named One of the Best Workplaces for Innovators by Fast Company

Retrieved on: 
Wednesday, July 12, 2023

Zoetis Inc. (NYSE:ZTS) has been named to Fast Company’s list of Best Workplaces for Innovators for 2023 .

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) has been named to Fast Company’s list of Best Workplaces for Innovators for 2023 .
  • Zoetis is the only stand-alone animal health company to be included on this year’s list which honors businesses that demonstrate a commitment to encouraging innovation at all levels.
  • “Our innovative culture means we are always seeking to understand how we can meet our customers’ next unmet need,” said Rob Polzer, Executive Vice President and President, Research & Development.
  • Fast Company editors and Accenture researchers worked together to score nearly 1,000 submissions, and a panel of eight distinguished judges reviewed and endorsed the top 100 companies.

Zoetis Announces Appointment of Ester Banque as President of U.S. Operations for World Leader in Animal Health

Retrieved on: 
Monday, July 10, 2023

Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced the addition of Ester Banque as Executive Vice President and President, U.S. Operations, for the company, effective July 10, 2023.
  • Ms. Banque is an accomplished global senior executive with over 30 years of experience in health sciences with top tier pharmaceutical companies.
  • Ester will be a member of the Zoetis Executive team and report to Chief Executive Officer Kristin Peck.
  • View the full release here: https://www.businesswire.com/news/home/20230709430714/en/
    Ester Banque joins Zoetis as Executive Vice President and President, U.S. Operations, effective July 10, 2023.

EQS-News: Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides

Retrieved on: 
Thursday, July 6, 2023

Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics.

Key Points: 
  • Numaferm, a Germany-based biotech company, specialized in the production of pepteins, and Zoetis, the global leading animal health company, have signed a licensing agreement for the development and production of defined veterinary therapeutics.
  • Pepteins are an underdeveloped class of molecules located between PEPTides and protEINS (with a length of 30-300 amino acids).
  • To date, peptein production via chemical synthesis or recombinant approaches is cumbersome, leading to time and resource-intensive development programs.
  • The partnership collaboration with Zoetis is another milestone for Numaferm, demonstrating the value of our proprietary technologies for pharma projects and beyond.”